Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mendel

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Expert Review of Vaccines|September 24, 2013
Translational sciences approach to RSV vaccine developmentVanessa Kurzweil, Roderick Tang, Mark Galinski, et al.
Antiviral Research|July 10, 2002
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivoJ A L Ives, J A Carr, D B Mendel, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 30, 2002
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceA Douglas Laird, Jmes G Christensen, Guangmin Li, et al.
Journal of Medicinal Chemistry|July 3, 1998
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitorsC U Kim, W Lew, M A Williams, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 31, 2006
Transplanting the highly sensitized patient: The emory algorithmR A Bray, J D L Nolen, C Larsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivoJ G Christensen, R E Schreck, E Chan, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1994
1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivoN Bischofberger, M J Hitchcock, M S Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2013
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patientsSarah Walter, Amos Baruch, Jin Dong, et al.
Anti-Cancer Drug Design|July 11, 2000
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agentD B Mendel, A D Laird, B D Smolich, et al.
Journal of the American Chemical Society|January 29, 1997
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activityC U Kim, W Lew, M A Williams, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Expert Review of Vaccines|September 24, 2013
Translational sciences approach to RSV vaccine developmentVanessa Kurzweil, Roderick Tang, Mark Galinski, et al.
Antiviral Research|July 10, 2002
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivoJ A L Ives, J A Carr, D B Mendel, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 30, 2002
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceA Douglas Laird, Jmes G Christensen, Guangmin Li, et al.
Journal of Medicinal Chemistry|July 3, 1998
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitorsC U Kim, W Lew, M A Williams, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 31, 2006
Transplanting the highly sensitized patient: The emory algorithmR A Bray, J D L Nolen, C Larsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivoJ G Christensen, R E Schreck, E Chan, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1994
1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivoN Bischofberger, M J Hitchcock, M S Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2013
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patientsSarah Walter, Amos Baruch, Jin Dong, et al.
Anti-Cancer Drug Design|July 11, 2000
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agentD B Mendel, A D Laird, B D Smolich, et al.
Journal of the American Chemical Society|January 29, 1997
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activityC U Kim, W Lew, M A Williams, et al.
Pageof 11